HAIC plus Camrelizumab and Rivoceranib for advanced mixed liver-bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called mixed hepatocellular-cholangiocarcinoma (features of both liver and bile duct cancer), confirmed by a biopsy.
- Your cancer cannot be removed with surgery or treated with local methods like ablation or embolization.
- You have not had any prior systemic (body-wide) cancer therapy for this condition, including immunotherapy or targeted drugs.
- You have not previously received HAIC (chemotherapy infused into the liver artery).
- Your liver function is fairly good (Child-Pugh score of 5 to 7, a measure of liver health) and you are well enough to walk and care for yourself (ECOG performance status 2 or lower).
- If you have hepatitis B, the virus is well controlled with medication (viral load below 100 IU/mL) and you are on antiviral treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests combining a liver-directed chemotherapy infusion (HAIC) with immunotherapy to shrink advanced bile duct cancer that cannot be removed surgically. The goal is to slow tumor growth and improve survival.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Hear when a new Mixed Hepatocellular-cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.